Echocardiography and Nuclear Scintigraphy in the Diagnosis of Transthyretin Cardiac Amyloidosis.

Abstract

A 94-year-old man presented with worsening dyspnea and orthopnea of 4 days' duration. Physical examination revealed jugular venous distention, diminished breath sounds, and pitting edema of the lower extremities. An electrocardiogram (Fig. 1) revealed conduction abnormalities, low QRS voltage, and an old myocardial infarction; a chest radiograph (Fig. 2) revealed cardiomegaly. These findings prompted us to obtain speckle-tracking echocardiograms (Figs. 3A–B), which revealed speckling of thickened myocardium, normal left ventricular (LV) size, biatrial enlargement, and a plethoric inferior vena cava. A strain imaging map (Fig. 3C) revealed relative apical sparing of LV function. Together, these findings raised suspicion of a restrictive cardiomyopathy, specifically amyloidosis. To confirm this diagnosis, we performed technetium-99m pyrophosphate (PYP) nuclear scintigraphy and serum immunoassays. The PYP nuclear scintigram was strongly positive for cardiac uptake of the radiotracer (Fig. 4), thus establishing the diagnosis of transthyretin cardiac amyloidosis. Serum protein electrophoresis (SPEP) revealed no monoclonal protein, and the serum free light chain (SFLC) ratio was normal.Identifying a specific cause of heart failure is important for both prognosis and treatment.1 An astute clinician recognizes the clinical, electrocardiographic, and echocardiographic signs of amyloidosis and performs other tests to confirm the diagnosis. Echocardiographic findings suggestive of amyloidosis include an LV wall thickness greater than 1.5 cm (also seen in hypertrophic cardiomyopathy but otherwise unusual, even in the presence of hypertension and aortic stenosis) and a characteristic “cherry on top” strain pattern (readily confirmed with current technology and more diagnostically sensitive and specific than wall thickness and speckling).2 Advanced testing can include cardiac magnetic resonance (CMR) imaging, nuclear scintigraphy, serum immunoassays, and endomyocardial biopsy. Although CMR is both sensitive and specific for cardiac amyloidosis, it cannot reliably distinguish between the light-chain and transthyretin subtypes.3 On the other hand, the combination of PYP nuclear scintigraphy,4 SPEP, and SFLC5 testing can distinguish between them, which is especially important in guiding treatment. Endomyocardial biopsy is reserved for cases in which noninvasive test results are inconclusive.